Small molecule inhibition of the viral main protease (Mpro) has been a successful anti-viral therapeutic strategy in HIV and HCV. Structural insight on the SARS-CoV-2 Mpro and previous small molecule experience with intravenous SARS-CoV-1 inhibitors provided an advanced starting point for an oral Mpro inhibitor program in response to the COVID-19 outbreak. The synthesis of PF-07321332, a potent, oral, first in class SARS-CoV-2 Mpro for the treatment of COVID-19 will be described.

Synthesis of PF-07321332 at lightspeed: Oral inhibitor of the SARS-CoV-2 main protease for the treatment of COVID-19

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.